Monographie - Epirubicin hydrochloride

Ultimo aggiornamento :
29/10/2024

Epirubicin hydrochloride

Struttura chimica

Nome commerciale

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Anthracine	Malaysia
Axirubicine	Germania
Bendaepi	Germania
Binarin	Messico
Bioepycina	Polonia
Crisabon	Argentina
Cuatroepi	Argentina
Ecclepia	Romania
Elebicin	Messico
Ellence	Stati Uniti d’America
Epi Cell	Germania
Epidoxo	Argentina, Chile, Venezuela
Epifil	Ecuador
Epilem	Colombia, Messico
Epimedac	Germania
Epirubicin	Arabia Saudita, Australia, Austria, Belgio, Danimarca, Gran Bretagna, Islanda, nuova Zelanda, Svezia, Svizzera, Turchia, Ungheria
Epirubicina	Argentina, Colombia, Ecuador, Messico, Romania, Spagna
Epirubicine	Belgio, Francia, Svizzera
Farmarubicin	Turchia
Farmorubicin	Arabia Saudita, Austria, Brasile, Danimarca, Finlandia, Grecia, Norvegia, Svezia, Svizzera
Farmorubicin CSV	Africa del Sud
Farmorubicin PFS	Croazia, Polonia, Slovenia
Farmorubicin RD	Brasile, Polonia, russo, Svizzera
Farmorubicin RTU	Paesi Bassi
Farmorubicina	Brasile, Italia, Portogallo, Spagna
Farmorubicine	Belgio, Francia
Pharmorubicin	Gran Bretagna

Bibliografia : Epirubicin hydrochloride

	tipo	pubblicazione
148	Rivista	Dine T, Cazin JC, Gressier B, Luycks M, Brunet C, Cazin M, Goudaliez F, Mallevais ML, Toraub I. Stability and compatibility of four anthracyclines: doxorubicin, epirubicin, daunorubicin and pirarubicin with PVC infusion bags. Pharm Weekbl [Sci] 1992 ; 14: 365-369.
525	Rivista	De Vroe C, De Muynck C, Remon JP, Samsom M. A study on the stability of three antineoplastic drugs and on their sorption by IV delivery systems and end-line filters. Int J Pharm 1990 ; 65: 49-56.
683	Rivista	Walker SE, Lau DWC, DeAngelis C, Iazetta J, Coons C. Epirubicin stability in syringes and glass vials and evaluation of chemical contamination. Can J Hosp Pharm 1990 ; 43: 265-272.
686	Rivista	Wood MJ, Irwin WJ, Scott DK. Stability of doxorubicin, daunorubicin and epirubicin in plastic syringes and minibags. J Clin Pharm Ther 1990 ; 15: 279-289.
887	Rivista	Pujol M, Munoz M, Prat J, Giona V, De Bolos J. Stability study of epirubicin in NaCl 0.9% injection. Ann Pharmacotherapy 1997 ; 31: 992-995.
1237	Rivista	Keusters L, Stolk LML, Umans R, Van Asten P. Stability of solutions of doxorubicin and epirubicin in plastic minibags for intravesical use after storage at -20°C and thawing by microwave radiation. Pharm Weekbl [Sci] 1986 ; 8: 194-197.
1265	Rivista	Wood MJ, Irwin WJ, Scott DK. Photodegradation of doxorubicin, daunorubicin and epirubicin measured by high-performance liquid chromatography. J Clin Pharm Ther 1990 ; 15: 291-300.
1317	Rivista	Adams PS, Haines-Hutt RF, Bradford E, Palmer A, Rowland CG. Pharmaceutical aspects of home infusion therapy for cancer patients. Pharm J 1987 ; 238: 476-478.
1662	Rivista	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1823	Rivista	Sewell GJ, Rigby-Jones AE, Priston MJ. Stability of intravesical epirubicin infusion: a sequential temperature study. J Clin Pharm Ther 2003 ; 28: 349-353.
1897	Rivista	Sautou-Miranda V, Brigas F, Thibault M, Chopineau J. Compatibility of doxorubicin, daunorubicin and epirubicin with low-density polyethylene and polyvinyl chloride, and stability in various conditions of storage. EJHP 2001 ; 7, 3: 108-115.
1955	Rivista	Trissel LA, Zhang Y. Palonosetron HCl compatibility and stability with doxorubicin HCl and epirubicin HCl during simulated Y-site administration. Ann Pharmacotherapy 2005 ; 39: 280-283.
2168	Rivista	Ozdemir FA, Anilanmert B, Pekin M. Spectrophotometric investigation of the chemical compatibility of the anticancer irinotecan-HCl and epirubicin-HCl in the same infusion solution. Cancer Chemother Pharmacol 2005 ; 56, 5: 529-534.
2257	Laboratorio	Stability of epirubicin "Ebewe" infusion solutions. Ebewe Pharma 2007
3473	Rivista	Bennis Y, Savry A, Correard F, Montana M, Sauzet C, Gauthier-Villano L, Pisano P, Pourroy B. Stability of a highly concentrated solution of epirubicin for conventional transcatheter arterial chemoembolization. Int J Pharm 2015 ; 495, 2: 956-962.
3474	Laboratorio	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3632	Laboratorio	Epirubicine (Epirubicine Hospira®) - Summary of Product Characteristics Hospira 2017
3670	Rivista	Sewell G, Massimini M. Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system. EJOP 2014 ; 8, 3: 26-30.
3708	poster	Sarakbi I, Thiesen J, Krämer I. Compatibility of epirubicin-loaded DC Beads with different contrast media. ECOP 2 Krakow 2014
3918	Rivista	Sarakbi I, Krämer I. Compatibility of epirubicin-loaded DC bead™ with different non-ionic contrast media. J Oncol Pharm Practice 2016 ; 22: 749-756.
4352	Rivista	Li J, Yao C, Xu Y, Ping P, Yin H, Sun Y. In vitro compatibility and stability of admixtures containing etoposide, epirubicin hydrochloride and vindesine sulphate in a single infusion bag. J Clin Pharm Ther 2019 ; 44: 875-882.

Mentions Légales